Biomarin Pharmaceutical (NAS:BMRN) Total Current Liabilities

: $598 Mil (As of Mar. 2023)

View and export this data going back to 1999. Start your Free Trial

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Biomarin Pharmaceutical's total current liabilities for the quarter that ended in Mar. 2023 was $598

Biomarin Pharmaceutical Total Current Liabilities Historical Data

The historical data trend for Biomarin Pharmaceutical's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data

Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22

Total Current Liabilities
523.24 932.50 492.55 546.50 588.88

Biomarin Pharmaceutical Quarterly Data

Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23

Total Current Liabilities 490.42 464.73 521.02 588.88 598.23

Biomarin Pharmaceutical Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Biomarin Pharmaceutical's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 341.699 + 10.375

+ Other Current Liabilities + Current Deferred Liabilities

= 236.099 + 0.711

= 589

Biomarin Pharmaceutical's Total Current Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 438.652 + 9.251

+ Other Current Liabilities + Current Deferred Liabilities

= 150.328 + 0

= 598

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Biomarin Pharmaceutical Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (NAS:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Total Current Liabilities

Comparable Companies

NAS:RPRX NAS:INCY NAS:TECH NAS:SRPT NAS:LEGN NAS:APLS NAS:ALNY NAS:UTHR NAS:RXDX NAS:BGNE OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN NAS:MRNA XKRX:207940 NAS:SGEN OCSE:GMAB NAS:BNTX HKSE:02269

Traded in Other Exchanges

BMRN:Mexico BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

Executives

Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901

Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901

Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139

Andrea Acosta officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST, SAN RAFAEL CA 94901

Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901

Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807

Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015

Willard H Dere director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799

Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018

Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612

Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901

Jeffrey Robert Ajer officer: SVP, Chief Commercial Of C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949

Daniel K Spiegelman officer: EVP, Chief Financial Officer MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003

Brian Mueller officer: VP, Corporate Controller C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949

Kenneth Bate director C/O MILLENNIUM PHARMACEUTICALS INC, 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139

Biomarin Pharmaceutical (NAS:BMRN) Headlines

From GuruFocus

BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
By PRNewswire 06-24-2022

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO� (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
By PRNewswire 07-11-2022

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN� (valoctocogene roxaparvovec), Approved by European Commission (EC)
By PRNewswire 08-24-2022

BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO� (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
By PRNewswire 06-23-2022

BioMarin to Participate in Two Upcoming Investor Conferences
By PRNewswire 11-03-2022

BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
By PRNewswire 07-14-2022

BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
By PRNewswire 07-10-2022

BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
By PRNewswire 06-20-2022

BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO� (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
By PRNewswire 07-03-2022

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO� (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
By PRNewswire 06-21-2022

Other Sources

Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
By CNBC 2022-12-21

Cramer's lightning round: I would hold onto Biomarin Pharmaceutical
By CNBC 2023-01-11

Biotech Stock Finds Favor Among Mutual Fund Managers
By Yahoo Finance 2022-12-23

Earnings growth outpaced the 29% return delivered to BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders over the last year
By Yahoo Finance 2023-01-07

BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN�)
By Yahoo Finance 2022-10-26

BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
By Yahoo Finance 2023-01-30

2 Top Biotech Stocks Defying the Bear Market
By Yahoo Finance 2023-01-10

BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
By Yahoo Finance 2022-11-07

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
By Yahoo Finance 2022-10-21

$BMRN - BioMarin: Opportunity To Score Home Run With Latest Regulatory Advancements. Biomarin Opportunity To Score Home Run With Latest Regulatory Advancements
By Seekingalpha 2023-01-30

European Medicines Agency Validates Application for Extension of Indication for VOXZOGO� (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
By Yahoo Finance 2023-01-03

Biomarin Posts Lower Q3 Loss, But Lags Street Consensus, Reaffirms Revenue Outlook
By Yahoo Finance 2022-10-27

BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
By Yahoo Finance 2023-01-04

BioMarin�s Gene Therapy Cuts Annual Bleeds by 80% Over 3 Years
By Bloomberg 2023-01-08

3 Drug Stocks With Promising Pipelines for 2023
By Yahoo Finance 2023-01-23

Biomarin Pharmaceutical Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Current Liabilities																490.42	464.73	521.02	588.88	598.23

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	341.699	+	10.375
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	236.099	+	0.711
	=	589

Erin Burkhart	officer: GVP, Chief Accounting Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Andrea Acosta	officer: GVP, Chief Accouning Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST, SAN RAFAEL CA 94901
Charles Greg Guyer	officer: EVP, Chief Technical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Robert J. Hombach	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Willard H Dere	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Dennis Slamon	director	770 LINDARO STREET, SAN RAFAEL CA 94901
Jeffrey Robert Ajer	officer: SVP, Chief Commercial Of	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Daniel K Spiegelman	officer: EVP, Chief Financial Officer	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Brian Mueller	officer: VP, Corporate Controller	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Kenneth Bate	director	C/O MILLENNIUM PHARMACEUTICALS INC, 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139